Off-the-Shelf CAR-T cells take on tough leukemia
NCT ID NCT07432100
First seen Mar 29, 2026 · Last updated May 23, 2026 · Updated 7 times
Summary
This early-stage trial tests a new type of immunotherapy called universal CLL1 CAR-T cells for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatment. The therapy uses donor T cells engineered to find and attack AML cells while sparing healthy blood stem cells. The study will enroll 20 participants to evaluate safety, how well the cells work, and how long they last in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.